Literature DB >> 25033984

Termination of immune activation: an essential component of healthy host immune responses.

Barry A Kane1, Katherine J Bryant, H Patrick McNeil, Nicodemus T Tedla.   

Abstract

The ideal immune response is rapid, proportionate and effective. Crucially, it must also be finite. An inflammatory response which is disproportionate or lasts too long risks injury to the host; chronic un-regulated inflammation in autoimmune diseases is one example of this. Thus, mechanisms to regulate and ultimately terminate immune responses are central to a healthy immune system. Despite extensive knowledge of what drives immune responses, our understanding of mechanisms of immune termination remains relatively sparse. It is clear that such processes are more complex than a one-dimensional homeostatic balance. Recent discoveries have revealed ever more nuanced mechanisms of signal termination, such as intrinsically self-limiting signals, multiple inhibitory mechanisms acting in tandem and activating proteins behaving differently in a variety of contexts. This review will summarise some important mechanisms, including termination by immunoreceptor tyrosine-based inhibitory motifs (ITIM), inhibition by soluble antagonists, receptor endocytosis or ubiquitination, and auto-inhibition by newly synthesised intracellular inhibitory molecules. Several recent discoveries showing immunoreceptor tyrosine-based activation motifs transducing inhibitory signals, ITIM mediating activating responses and the possible roles of immunoreceptor tyrosine-based switch motifs will also be explored.

Entities:  

Mesh:

Year:  2014        PMID: 25033984      PMCID: PMC6741560          DOI: 10.1159/000363449

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  6 in total

1.  Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells.

Authors:  Yi Jia; Huifeng Yu; Steve M Fernandes; Yadong Wei; Anabel Gonzalez-Gil; Mary G Motari; Katarina Vajn; Whitney W Stevens; Anju T Peters; Bruce S Bochner; Robert C Kern; Robert P Schleimer; Ronald L Schnaar
Journal:  J Allergy Clin Immunol       Date:  2015-03       Impact factor: 10.793

Review 2.  Viral Manipulation of Host Inhibitory Receptor Signaling for Immune Evasion.

Authors:  Eugenia Z Ong; Kuan Rong Chan; Eng Eong Ooi
Journal:  PLoS Pathog       Date:  2016-09-01       Impact factor: 6.823

3.  Serum Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) Is Increased in Patients with Multiple Sclerosis and Is a Strong Independent Indicator of Disease Severity; 6.7kbp LILRA3 Gene Deletion Is Not Associated with Diseases Susceptibility.

Authors:  Hongyan An; Chai Lim; Gilles J Guillemin; Ute Vollmer-Conna; William Rawlinson; Katherine Bryant; Nicodemus Tedla
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

Review 4.  Epigenetics in Sepsis: Understanding Its Role in Endothelial Dysfunction, Immunosuppression, and Potential Therapeutics.

Authors:  Deborah Cross; Ruth Drury; Jennifer Hill; Andrew J Pollard
Journal:  Front Immunol       Date:  2019-06-18       Impact factor: 7.561

Review 5.  Immunoregulatory Property of C-Type Lectin-Like Receptors in Fibrosing Interstitial Lung Diseases.

Authors:  Wiwin Is Effendi; Tatsuya Nagano; Helmia Hasan; Resti Yudhawati
Journal:  Int J Mol Sci       Date:  2020-05-22       Impact factor: 5.923

6.  Leukocyte immunoglobulin-like receptor A3 is increased in IBD patients and functions as an anti-inflammatory modulator.

Authors:  X Lan; F Liu; J Ma; Y Chang; X Lan; L Xiang; X Shen; F Zhou; Q Zhao
Journal:  Clin Exp Immunol       Date:  2020-11-12       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.